Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04583423




Registration number
NCT04583423
Ethics application status
Date submitted
5/10/2020
Date registered
12/10/2020
Date last updated
29/04/2024

Titles & IDs
Public title
A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001)
Scientific title
A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis.
Secondary ID [1] 0 0
MK-3655-001
Secondary ID [2] 0 0
3655-001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Nonalcoholic Steatohepatitis 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Metabolic and Endocrine 0 0 0 0
Metabolic disorders
Diet and Nutrition 0 0 0 0
Obesity

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - MK-3655
Treatment: Drugs - Placebo

Experimental: MK-3655 50 mg - Following a 2-week placebo run-in, participants will receive MK-3655 50 mg by subcutaneous (SC) injection once every 4 weeks (Q4W) for 52 weeks.

Experimental: MK-3655 100 mg - Following a 2-week placebo run-in, participants will receive MK-3655 100 mg by SC injection Q4W for 52 weeks.

Experimental: MK-3655 300 mg - Following a 2-week placebo run-in, participants will receive MK-3655 300 mg by SC injection Q4W for 52 weeks.

Placebo Comparator: Placebo - Following a 2-week placebo run-in, participants will receive Placebo by SC injection Q4W for 52 weeks.


Treatment: Drugs: MK-3655
MK-3655 50, 100 or 300 dose for injection

Treatment: Drugs: Placebo
Matching placebo to MK-3655
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis After 52 Weeks
Timepoint [1] 0 0
Week 52
Primary outcome [2] 0 0
Percentage of Participants Who Experienced an Adverse Event (AE)
Timepoint [2] 0 0
Up to 64 weeks
Primary outcome [3] 0 0
Percentage of Participants Discontinuing Study Medication Due to an AE
Timepoint [3] 0 0
Up to 52 weeks
Secondary outcome [1] 0 0
Mean Percent Relative Reduction From Baseline in Liver Fat Content (LFC) After 24 Weeks
Timepoint [1] 0 0
Baseline and Week 24
Secondary outcome [2] 0 0
Percentage of Participants With =1 Stage Improvement in Fibrosis Without Worsening of Steatohepatitis Assessed With the NASH CRN Scoring System After 52 Weeks
Timepoint [2] 0 0
Week 52
Secondary outcome [3] 0 0
Percentage of Participants With =2 Point Improvement in NAS With =1 Point Improvement in Inflammation or Ballooning Without Worsening of Fbrosis by Histology (Evaluated by BICR) After 52 Weeks
Timepoint [3] 0 0
Week 52

Eligibility
Key inclusion criteria
- Has histological confirmation of NASH

- Is a male or female aged 18 years to 80 years (in Japan and Taiwan aged 20 to 80
years)

- Has a body mass index (BMI) =25 kg/m^2 and =50 kg/m^2 and stable weight for the past 3
months

- Has no history of Type 2 diabetes mellitus (T2DM) OR a history of T2DM controlled by
diet or stable doses of antihyperglycemic agents (AHAs)

- Contraceptive use by male participants should be consistent with local regulations.

- A female participant is eligible to participate if she is not pregnant or
breastfeeding, and she is not a woman of child-bearing potential (WOCBP) OR she is a
WOCBP and uses a contraceptive method that is highly effective during the intervention
period and for at least 16 weeks after the last dose of study intervention.
Minimum age
18 Years
Maximum age
80 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion Criteria

- Has presence of cirrhosis on liver biopsy

- Has Type 1 diabetes

- Has a history of malignancy, unless cancer free =5 years, or is under evaluation for
active or suspected malignancy except for adequately treated basal cell or squamous
cell skin cancer or in situ cervical cancer

- Has a history of bariatric surgery =5 years before study participation

- Has undergone a major surgical procedure =3 months before study participation or has
major surgery planned during the study

- Has a history or evidence of chronic liver disease other than NASH. Individuals with a
history of Hepatitis B or C may be eligible for participation.

- Has significant systemic or major illnesses other than liver disease, including recent
events (=6 months before study entry) of congestive heart failure, unstable coronary
artery disease, arterial revascularization, pulmonary disease, renal failure, stroke,
transient ischemic attack, or organ transplantation

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
11/11/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
13/04/2023
Sample size
Target
Accrual to date
Final
183
Recruitment in Australia
Recruitment state(s)
NSW,SA
Recruitment hospital [1] 0 0
Royal Prince Alfred Hospital ( Site 0102) - Camperdown
Recruitment hospital [2] 0 0
St George Hospital ( Site 0104) - Kogarah
Recruitment hospital [3] 0 0
Flinders Medical Centre ( Site 0107) - Bedford Park
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2217 - Kogarah
Recruitment postcode(s) [3] 0 0
5042 - Bedford Park
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Iowa
Country [8] 0 0
United States of America
State/province [8] 0 0
Louisiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Mississippi
Country [10] 0 0
United States of America
State/province [10] 0 0
Missouri
Country [11] 0 0
United States of America
State/province [11] 0 0
Nevada
Country [12] 0 0
United States of America
State/province [12] 0 0
New York
Country [13] 0 0
United States of America
State/province [13] 0 0
Pennsylvania
Country [14] 0 0
United States of America
State/province [14] 0 0
Tennessee
Country [15] 0 0
United States of America
State/province [15] 0 0
Texas
Country [16] 0 0
United States of America
State/province [16] 0 0
Virginia
Country [17] 0 0
Argentina
State/province [17] 0 0
Buenos Aires
Country [18] 0 0
Argentina
State/province [18] 0 0
Caba
Country [19] 0 0
Argentina
State/province [19] 0 0
Santa Fe
Country [20] 0 0
Canada
State/province [20] 0 0
British Columbia
Country [21] 0 0
Canada
State/province [21] 0 0
Ontario
Country [22] 0 0
Canada
State/province [22] 0 0
Quebec
Country [23] 0 0
Chile
State/province [23] 0 0
Biobio
Country [24] 0 0
Chile
State/province [24] 0 0
Coquimbo
Country [25] 0 0
Chile
State/province [25] 0 0
Los Rios
Country [26] 0 0
Chile
State/province [26] 0 0
Region M. De Santiago
Country [27] 0 0
Chile
State/province [27] 0 0
Valparaiso
Country [28] 0 0
China
State/province [28] 0 0
Beijing
Country [29] 0 0
China
State/province [29] 0 0
Chongqing
Country [30] 0 0
China
State/province [30] 0 0
Guangdong
Country [31] 0 0
China
State/province [31] 0 0
Ningxia
Country [32] 0 0
China
State/province [32] 0 0
Shanghai
Country [33] 0 0
China
State/province [33] 0 0
Zhejiang
Country [34] 0 0
Colombia
State/province [34] 0 0
Distrito Capital De Bogota
Country [35] 0 0
France
State/province [35] 0 0
Alpes-Maritimes
Country [36] 0 0
France
State/province [36] 0 0
Aquitaine
Country [37] 0 0
France
State/province [37] 0 0
Auvergne
Country [38] 0 0
France
State/province [38] 0 0
Bourgogne
Country [39] 0 0
France
State/province [39] 0 0
Franche-Comte
Country [40] 0 0
France
State/province [40] 0 0
Haute-Vienne
Country [41] 0 0
France
State/province [41] 0 0
Hauts-de-Seine
Country [42] 0 0
France
State/province [42] 0 0
Meurthe-et-Moselle
Country [43] 0 0
France
State/province [43] 0 0
Nord
Country [44] 0 0
France
State/province [44] 0 0
Val-de-Marne
Country [45] 0 0
France
State/province [45] 0 0
Paris
Country [46] 0 0
Germany
State/province [46] 0 0
Baden-Wurttemberg
Country [47] 0 0
Germany
State/province [47] 0 0
Hessen
Country [48] 0 0
Germany
State/province [48] 0 0
Rheinland-Pfalz
Country [49] 0 0
Germany
State/province [49] 0 0
Sachsen
Country [50] 0 0
Germany
State/province [50] 0 0
Berlin
Country [51] 0 0
Greece
State/province [51] 0 0
Kentriki Makedonia
Country [52] 0 0
Hong Kong
State/province [52] 0 0
Hong Kong
Country [53] 0 0
Hong Kong
State/province [53] 0 0
Shatin
Country [54] 0 0
Israel
State/province [54] 0 0
Haifa
Country [55] 0 0
Israel
State/province [55] 0 0
Jerusalem
Country [56] 0 0
Israel
State/province [56] 0 0
Petah Tikva
Country [57] 0 0
Israel
State/province [57] 0 0
Ramat Gan
Country [58] 0 0
Israel
State/province [58] 0 0
Ramat Hasharon
Country [59] 0 0
Israel
State/province [59] 0 0
Tel Aviv
Country [60] 0 0
Italy
State/province [60] 0 0
Lombardia
Country [61] 0 0
Italy
State/province [61] 0 0
Modena
Country [62] 0 0
Italy
State/province [62] 0 0
Roma
Country [63] 0 0
Italy
State/province [63] 0 0
Verona
Country [64] 0 0
Japan
State/province [64] 0 0
Aichi
Country [65] 0 0
Japan
State/province [65] 0 0
Ehime
Country [66] 0 0
Japan
State/province [66] 0 0
Gifu
Country [67] 0 0
Japan
State/province [67] 0 0
Hokkaido
Country [68] 0 0
Japan
State/province [68] 0 0
Ishikawa
Country [69] 0 0
Japan
State/province [69] 0 0
Kagawa
Country [70] 0 0
Japan
State/province [70] 0 0
Kanagawa
Country [71] 0 0
Japan
State/province [71] 0 0
Nara
Country [72] 0 0
Japan
State/province [72] 0 0
Osaka
Country [73] 0 0
Japan
State/province [73] 0 0
Fukui
Country [74] 0 0
Japan
State/province [74] 0 0
Hiroshima
Country [75] 0 0
Japan
State/province [75] 0 0
Kagoshima
Country [76] 0 0
Japan
State/province [76] 0 0
Kyoto
Country [77] 0 0
Japan
State/province [77] 0 0
Okayama
Country [78] 0 0
Japan
State/province [78] 0 0
Tokyo
Country [79] 0 0
Korea, Republic of
State/province [79] 0 0
Kyonggi-do
Country [80] 0 0
Korea, Republic of
State/province [80] 0 0
Pusan-Kwangyokshi
Country [81] 0 0
Korea, Republic of
State/province [81] 0 0
Seoul
Country [82] 0 0
Korea, Republic of
State/province [82] 0 0
Incheon
Country [83] 0 0
Malaysia
State/province [83] 0 0
Kuala Lumpur
Country [84] 0 0
Mexico
State/province [84] 0 0
Distrito Federal
Country [85] 0 0
Mexico
State/province [85] 0 0
Jalisco
Country [86] 0 0
Mexico
State/province [86] 0 0
Yucatan
Country [87] 0 0
Mexico
State/province [87] 0 0
Mexico City
Country [88] 0 0
New Zealand
State/province [88] 0 0
Canterbury
Country [89] 0 0
New Zealand
State/province [89] 0 0
Auckland
Country [90] 0 0
Puerto Rico
State/province [90] 0 0
Rio Piedras
Country [91] 0 0
Puerto Rico
State/province [91] 0 0
San Juan
Country [92] 0 0
Russian Federation
State/province [92] 0 0
Moskva
Country [93] 0 0
Russian Federation
State/province [93] 0 0
Sankt-Peterburg
Country [94] 0 0
Spain
State/province [94] 0 0
Cantabria
Country [95] 0 0
Spain
State/province [95] 0 0
La Coruna
Country [96] 0 0
Spain
State/province [96] 0 0
Madrid
Country [97] 0 0
Spain
State/province [97] 0 0
Sevilla
Country [98] 0 0
Spain
State/province [98] 0 0
Barcelona
Country [99] 0 0
Sweden
State/province [99] 0 0
Stockholms Lan
Country [100] 0 0
Sweden
State/province [100] 0 0
Uppsala Lan
Country [101] 0 0
Taiwan
State/province [101] 0 0
Chiayi
Country [102] 0 0
Taiwan
State/province [102] 0 0
Taichung
Country [103] 0 0
Taiwan
State/province [103] 0 0
Taoyuan
Country [104] 0 0
Taiwan
State/province [104] 0 0
Kaohsiung
Country [105] 0 0
Taiwan
State/province [105] 0 0
Tainan
Country [106] 0 0
Taiwan
State/province [106] 0 0
Taipei
Country [107] 0 0
Turkey
State/province [107] 0 0
Ankara
Country [108] 0 0
Turkey
State/province [108] 0 0
Istanbul
Country [109] 0 0
Turkey
State/province [109] 0 0
Izmir

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Merck Sharp & Dohme LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study will evaluate the effect of each dose of MK-3655 versus placebo on the percentage
of individuals with NASH resolution without worsening of fibrosis after 52 weeks. The primary
hypothesis of the study is that at least 1 dose of MK-3655 is superior to placebo with
respect to the percentage of individuals with NASH resolution without worsening of fibrosis
after 52 weeks.
Trial website
https://clinicaltrials.gov/ct2/show/NCT04583423
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Medical Director, MD
Address 0 0
Merck Sharp & Dohme LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04583423